Drug intelligence / Profile preview

inorganic arsenic

Development stage
Unknown
Modality
Small Molecules
Administration
Oral, Inhalation, Dermal
01

Overview

Inorganic arsenic refers to arsenic compounds where arsenic binds with elements such as sulfur, oxygen, and chlorine rather than carbon-containing molecules. The most common forms are **arsenite** (trivalent arsenic, As³⁺) and **arsenate** (pentavalent arsenic, As⁵⁺), with arsenic trioxide (As₂O₃) being the most prevalent form in air. Inorganic arsenic compounds are **highly toxic** and classified as **confirmed human carcinogens** by multiple health agencies including IARC, EPA, and DHHS. The toxic mechanisms involve: (1) arsenite binding to sulfhydryl groups in critical enzymes, disrupting cellular respiration and ATP formation, particularly affecting pyruvate dehydrogenase in the citric acid cycle, and (2) arsenate substituting for phosphate in biochemical reactions, causing rapid hydrolysis of high-energy bonds and uncoupling oxidative phosphorylation. Historically used extensively in pesticides, wood preservatives (CCA-treated wood), and medicine, most agricultural uses have been banned in the United States due to toxicity concerns. However, **arsenic trioxide** has been reintroduced as a pharmaceutical agent for treating **acute promyelocytic leukemia**. Inorganic arsenic is also released into the environment through mining, smelting operations, coal combustion, and is used in semiconductor production (as gallium arsenide), alloys, and glass manufacturing.

Other names
arsenitearsenatearsenic trioxideAs2O3As-2O3As 2O3arsenic acidwhite arsenic
02

Targets

TXNRD2 (Thioredoxin reductase 2)GSR (Glutathione reductase)α-KGDH (Alpha-ketoglutarate dehydrogenase complex)GPX4 (Glutathione peroxidase 4)VDT/Cys-SH (Vicinal dithiol and reduced cysteine residues in cellular proteins)PDH (Pyruvate dehydrogenase complex)

Beyond the preview

Go deeper on inorganic arsenic.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on inorganic arsenic.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call